Bruzzese Antonella, Santoro Cristina, Baldacci Erminia, Ferretti Antonietta, Pieroni Simone, Serrao Alessandra, Foà Robin, Chistolini Antonio
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome Italy.
Blood Coagul Fibrinolysis. 2019 Sep;30(6):304-307. doi: 10.1097/MBC.0000000000000835.
: Pregnancy carries a high risk of thromboembolic complications, especially in the postpartum period. This risk is particularly high in women with inherited thrombophilias, among these antithrombin deficiency seems to carry the highest risk. In this case, the use of low molecular weight heparin (LMWH) is recommended, while the use of antithrombin concentrate is controversial. We report our experience of seven pregnancies occurred in five women: two, with a personal and familiar history negative for venous thromboembolism, were treated with LMWH during pregnancy and antithrombin concentrate immediately before and after the delivery. The other three women had a personal and familiar history positive for venous thromboembolism and were treated with LMWH and antithrombin concentrate during all the pregnancy and the postpartum period. No thromboembolic or hemorrhagic complications were observed in both groups, demonstrating that our strategy could be safe and effective.
妊娠具有发生血栓栓塞并发症的高风险，尤其是在产后时期。在患有遗传性血栓形成倾向的女性中，这种风险尤其高，其中抗凝血酶缺乏似乎风险最高。在这种情况下，推荐使用低分子量肝素（LMWH），而使用抗凝血酶浓缩物存在争议。我们报告了五名女性发生的七次妊娠的经验：两名女性个人及家族史均无静脉血栓栓塞，孕期接受LMWH治疗，分娩前后即刻接受抗凝血酶浓缩物治疗。另外三名女性个人及家族史有静脉血栓栓塞阳性，在整个孕期及产后均接受LMWH和抗凝血酶浓缩物治疗。两组均未观察到血栓栓塞或出血并发症，表明我们的策略可能是安全有效的。
